Actively Recruiting
Deployment of the Multidisciplinary Prospective Cohort IMMINeNT for Immune-Mediated Inflammatory Diseases
Led by University Hospital, Lille · Updated on 2026-05-05
2200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University Hospital, Lille
Lead Sponsor
F
FHU IMMINeNT
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying immune-mediated inflammatory diseases (IMIDs), which commonly affect younger adults and significantly impact patients' quality of life, work, social, and emotional well-being. These diseases share similar biological mechanisms and treatments called targeted therapies. Despite advances, more research is needed to understand treatment effectiveness, resistance, and side effects. The study aims to create a large clinical and biological database called the IMMINeNT cohort along with a biobank to find new biomarkers and factors affecting disease activity, severity, treatment response, and patient quality of life. Participants will be enrolled in the IMMINeNT cohort and will undergo regular assessments including collecting blood samples for biobanking and genetic analysis. They will also complete quality of life questionnaires annually. This observational approach will involve multiple departments such as dermatology, internal medicine, neurology, pneumology, and rheumatology. The study is designed for long-term follow-up over 10 years to monitor changes in disease activity scores, quality of life measures, and serious infections. Throughout the study, participants will be evaluated yearly using specific disease scores like SLEDAI for lupus and BASDAI for psoriatic arthritis, as well as the SF-12 quality of life questionnaire. Blood samples will be collected at each visit to support genetic and other biological research. The study will track disease flares, exacerbations, and severe infections annually for up to 10 years. Participants will be followed closely while continuing their usual medical care, contributing valuable information to improve understanding and treatment of IMIDs.
CONDITIONS
Brief Title
Deployment o the Multidisciplinary Prospective Cohort Imminent
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient followed for their immune-mediated inflammatory disease in one of the participating hospital departments (dermatology, internal medicine, neurology, pneumology, rheumatology)
- Covered by social security or health insurance
- Able to understand the study, provide written informed consent, and comply with study procedures
You will not qualify if you...
- Unable to receive informed information or participate in the entire study for administrative reasons
- Pregnant or breastfeeding women
- Persons deprived of liberty
- Protected minors or adults
- Persons who refuse or cannot give informed consent
- Persons in emergency situations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 10 years
Participants who have consented are observed with annual assessments including blood sample collection for biobanking and genetic analysis, and completion of the SF-12 quality of life questionnaire.
Annual visits for up to 10 years
Trial Site Locations
Total: 1 location
1
Hop Claude Huriez Chu Lille
Lille, France, 59037
Actively Recruiting
Research Team
D
David Launay, MD,PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here